Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (155): sc-65830

AChRα1 Antibody (155) is a rat monoclonal IgG2a antibody that detects AChRα1 in mouse, rat, and Torpedo by western blotting (WB) and immunofluorescence (IF). AChRα1, also known as ACHRD, CHRNA, CMS2A, FCCMS, SCCMS, or CHRNA1, is a crucial multi-pass membrane protein composed of 482 amino acids, which plays a vital role in neuromuscular transmission. AChRα1 is primarily located at the postsynaptic membrane of the neuromuscular junction, where AChRα1 binds acetylcholine, facilitating the influx of ions through its transmembrane aqueous pore. Proper functioning of AChRα1 is essential for muscle contraction and overall neuromuscular function, as AChRα1 directly influences synaptic transmission. Notably, AChRα1 exists in two alternatively spliced isoforms; isoform 1 is exclusively expressed in skeletal muscle, while isoform 2 is widely distributed across various tissues, including the brain, heart, kidney, liver, lung, and thymus. The diverse expression of these isoforms highlights the importance of AChRα1 in both muscle and neuronal signaling pathways, making AChRα1 a significant target for research in neuromuscular disorders and synaptic function. Anti-AChRα1 antibody (155) is an invaluable tool for researchers aiming to explore the intricate mechanisms of neurotransmission and the physiological roles of this essential receptor.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (155) References:

1. Absence of beta-tropomyosin is a new cause of Escobar syndrome associated with nemaline myopathy.  |  Monnier, N., et al. 2009. Neuromuscul Disord. 19: 118-23. PMID: 19155175
2. Lifting the lid on unborn lethal Mendelian phenotypes through exome sequencing.  |  Shamseldin, HE., et al. 2013. Genet Med. 15: 307-9. PMID: 23037934
3. (-)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.  |  Arias, HR., et al. 2013. Neurochem Int. 63: 423-31. PMID: 23917086
4. Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis.  |  Bros-Facer, V., et al. 2014. Hum Mol Genet. 23: 4187-200. PMID: 24667415
5. Gene Polymorphisms for Both Auto-antigen and Immune-Modulating Proteins Are Associated with the Susceptibility of Autoimmune Myasthenia Gravis.  |  Li, HF., et al. 2017. Mol Neurobiol. 54: 4771-4780. PMID: 27501803
6. False positive acetylcholine receptor antibodies in a case of unilateral chronic progressive external ophthalmoplegia: case report and review of literature.  |  Rajput, R., et al. 2018. Orbit. 37: 385-388. PMID: 29333908
7. Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation.  |  Cetin, H., et al. 2019. Proc Natl Acad Sci U S A. 116: 21228-21235. PMID: 31570625
8. Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies.  |  Behbehani, R., et al. 2022. Neuroophthalmology. 46: 220-226. PMID: 35859633
9. Derepression may masquerade as activation in ligand-gated ion channels.  |  Tessier, CJG., et al. 2023. Nat Commun. 14: 1907. PMID: 37019877
10. Human muscle acetylcholine receptor alpha-subunit gene (CHRNA1) association with autoimmune myasthenia gravis in black, mixed-ancestry and Caucasian subjects.  |  Heckmann, JM., et al. 1996. J Autoimmun. 9: 175-80. PMID: 8738961

The preferred Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 antibody is Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (153): sc-65829.